Shares of MyoKardia Inc. (MYOK) touched an all-time high of $104.26 in intraday trading on Monday, before closing at $96.90, thanks to positive top-line data from the Company's phase III EXPLORER study of Mavacamten for the treatment of obstructive hypertrophic cardiomyopathy.
from RTT - Biotech https://ift.tt/2AdZYjM
via IFTTT
No comments:
Post a Comment